Edition:
United States

Profile: Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.14DKK
4:00am EST
Change (% chg)

kr.0.01 (+0.88%)
Prev Close
kr.1.13
Open
kr.1.14
Day's High
kr.1.14
Day's Low
kr.1.12
Volume
334,761
Avg. Vol
1,193,729
52-wk High
kr.2.10
52-wk Low
kr.0.93

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based company active in the biotechnology and pharmaceutical industry. It is primarily focused on the development of its transplant immunosuppression product candidate, LCP-Tacro. LCP-Tacro is being developed as a once-daily dosage version of tacrolimus for the treatment of kidney and liver transplant patients. Additionally, the Company develops pharmaceuticals in the cardiovascular therapeutic area, such as LCP-FenoChol (Fenoglide) for the treatment of dyslipidemia and hypercholesterolemia, and AtorFen, a fixed dose combination tablet of fenofibrate and atorvastatin. The Company utilizes its MeltDose technology platform for enhancing the bioavailability of compounds with low water solubility.

Company Address

Veloxis Pharmaceuticals A/S

2. Sal, Agern Alle 24
HOERSHOLM     2970

Company Web Links